Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

Background Everolimus is an oral mTOR-inhibitor. Preclinical data show synergistic effects of mTOR inhibition in combination with 5-fluorouracil-based anticancer therapy. The combination of everolimus with capecitabine seems therefore an attractive new, orally available, treatment regimen. Patients...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Deenen, Maarten J., Klümpen, Heinz-Josef, Richel, Dick J., Sparidans, Rolf W., Weterman, Mariette J., Beijnen, Jos H., Schellens, Jan H. M., Wilmink, Johanna W.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Springer US 2011
Pynciau:
Phase I Studies
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388253/
https://ncbi.nlm.nih.gov/pubmed/21809026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-011-9723-4
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg